Stay updated with breaking news from Ron Grunstein. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Ron Grunstein, MD, PhD, head of sleep and circadian research, Woolcock Institute of Medical Research, shares findings from a phase 1b study on the use of a novel orexin agonist in patients with narcolepsy type 1.
New analysis from SURMOUNT-1 support the use of GLP-1/GIP agonist tirzepatide to reduce weight in patients with OSA and obesity/overweight.
Alkermes will present new data for its investigational narcolepsy treatment, ALKS 2680, at SLEEP 2024 in Houston.
- Late-Breaking Abstracts Containing Data From the Full Narcolepsy Type 1 Cohort From the ALKS 2680 Phase 1b Study and Vibrance-1 Phase 2 Study Design Accepted for Poster Presentations - -
New insights into REM sleep and our emotions may change the way we treat mental health.